Analyst Ratings for [ALLO] Allogene Therapeutics, Inc.

8/8/24	Resumed	Outperform	X
ALLO Allogene Oppenheimer
$13 $11
5/31/24	Initiated	Overweight	X
ALLO Allogene Piper Sandler
$11
1/5/24	Downgrades	Buy Neutral	X
ALLO Allogene Guggenheim
1/5/24	Downgrades	Mkt Outperform Mkt Perform	X
ALLO Allogene JMP Securities
12/8/23	Initiated	Buy	X
ALLO Allogene Citigroup
$7
6/26/23	Resumed	Outperform	X
ALLO Allogene Oppenheimer
$28
3/21/23	Initiated	Mkt Perform	X
ALLO Allogene Bernstein
$6
1/24/23	Upgrades	Neutral Overweight	X
ALLO Allogene JP Morgan
$20 $11
1/6/23	Upgrades	Neutral Outperform	X
ALLO Allogene Robert W. Baird
$12
12/12/22	Downgrades	Buy Underperform	X
ALLO Allogene BofA Securities
$24 $9
8/10/22	Downgrades	Outperform Mkt Perform	X
ALLO Allogene Raymond James
7/15/22	Upgrades	Neutral Buy	X
ALLO Allogene Goldman
$9 $32
6/3/22	Initiated	Neutral	X
ALLO Allogene Robert W. Baird
$11
10/20/21	Initiated	Outperform	X
ALLO Allogene Cowen
10/8/21	Downgrades	Buy Neutral	X
ALLO Allogene Goldman
$71 $20
10/8/21	Downgrades	Buy Hold	X
ALLO Allogene Stifel
$44 $18
6/21/21	Resumed	Buy	X
ALLO Allogene Jefferies
$53
5/20/21	Upgrades	Hold Buy	X
ALLO Allogene Truist
$34 $41
5/14/21	Initiated	Buy	X
ALLO Allogene B. Riley Securities
$52
1/26/21	Upgrades	Hold Buy	X
ALLO Allogene Stifel
$33 $43
8/9/19	Initiated	Buy	X
ALLO Allogene BTIG Research
$37
6/5/19	Initiated	Neutral	X
ALLO Allogene ROTH Capital
$26
5/31/19	Initiated	Neutral	X
ALLO Allogene Guggenheim
5/23/19	Initiated	Hold	X
ALLO Allogene Stifel
3/29/19	Initiated	Overweight	X
ALLO Allogene Piper Jaffray
$50
3/15/19	Initiated	Outperform	X
ALLO Allogene Raymond James
3/14/19	Initiated	Outperform	X
ALLO Allogene William Blair
11/5/18	Initiated	Outperform	X
ALLO Allogene Cowen
11/5/18	Initiated	Buy	X
ALLO Allogene Goldman
11/5/18	Initiated	Buy	X
ALLO Allogene Jefferies
11/5/18	Initiated	Neutral	X
ALLO Allogene JP Morgan
$29

ALLO Allogene Therapeutics, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.